Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.39 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.34 |
| ▸ | OGA | O60502 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SMO | Q99835 | 1/20 | 0.31 |
| ▸ | PLG | P00747 | 1/20 | 0.30 |
| ▸ | PLAU | P00749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22296706 | 0.78 | BTK (0.34) | BTKKDM4EL3MBTL1 | |
| SCHEMBL14723341 | 0.78 | BTK (0.35) | BTK | |
| SCHEMBL9905543 | 0.75 | UGT2B7 (0.47) | BTKUGT2B7PTGS2PLGPLAU | |
| SCHEMBL9905545 | 0.75 | UGT2B7 (0.47) | BTKUGT2B7PTGS2PLGPLAU | |
| SCHEMBL28209215 | 0.75 | UGT2B7 (0.36) | UGT2B7OGAALDH1A1PTGS2NOS3 | |
| SCHEMBL29790356 | 0.75 | CYP2A6 (0.38) | UGT2B7OGAALDH1A1NOS3NOS1 | |
| SCHEMBL115262 | 0.75 | CYP2A6 (0.38) | UGT2B7OGAALDH1A1NOS3NOS1 | |
| SCHEMBL22811499 | 0.74 | BTK (0.33) | BTK | |
| SCHEMBL31201731 | 0.72 | LMNA (0.40) | UGT2B7OGAALDH1A1NOS3NOS1 | |
| SCHEMBL17154813 | 0.72 | LMNA (0.40) | UGT2B7OGAALDH1A1NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150297596-A1 | ISOXAZOLINES AS THERAPEUTIC AGENTS | ABBVIE INC. (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150297596-A1 | ISOXAZOLINES AS THERAPEUTIC AGENTS | ABBVIE INC. (US) | 2015-10-22 | — | — | US | disclosed |
| US-9029409-B2 | Isoxazolines as therapeutic agents | ABBVIE INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029409-B2 | Isoxazolines as therapeutic agents | ABBVIE INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20130023526-A1 | Isoxazolines as Therapeutic Agents | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| US-20130023526-A1 | Isoxazolines as Therapeutic Agents | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| WO-2012151158-A1 | ISOXAZOLINES AS THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2012-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297596-A1 | ISOXAZOLINES AS THERAPEUTIC AGENTS | CYP3A7, CYP11B2, CYP11B1 | BTK 2758/4885UGT2B7 9/4885OGA 3002/4885 |
| US-20130023526-A1 | Isoxazolines as Therapeutic Agents | CYP3A7, CYP11B2, CYP11B1 | BTK 2758/4885UGT2B7 9/4885OGA 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.